Article info
PDFResponse
Uncertainty, error and informed consent to challenge trials of COVID-19 vaccines: response to Steel et al
- Correspondence to Dr Arnon Keren, Department of Philosophy, University of Haifa, Haifa 3498838, Israel; akeren{at}research.haifa.ac.il
Citation
Uncertainty, error and informed consent to challenge trials of COVID-19 vaccines: response to Steel et al
Publication history
- Received August 14, 2020
- Accepted August 26, 2020
- First published September 8, 2020.
Online issue publication
November 27, 2020
Article Versions
- Previous version (8 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Other content recommended for you
- Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia
- Better recognition for research participants: what society should learn from covid-19
- COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement
- Ethics of research at the intersection of COVID-19 and black lives matter: a call to action
- Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy
- Do coronavirus vaccine challenge trials have a distinctive generalisability problem?
- Payment of COVID-19 challenge trials: underpayment is a bigger worry than overpayment
- Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines
- UK Research Ethics Committee’s review of the global first SARS-CoV-2 human infection challenge studies
- A framework for the promotion of ethical benefit sharing in health research